Studies on Interactions between Traditional Herbal and Western Medicines. V. Effects of Sho-saiko-to (Xiao-Cai-hu-Tang) on the Pharmacokinetics of Carbamazepine in Rats
Koji TAKARA, a and Teruyoshi YOKOYAMA (Japan SLC, Inc., Hamamatsu, Japan), weighing 170-190 g, were used throughout this study.
Evaluation of Serum Protein Binding of CBZ and CBZ-E in Vitro
The protein binding of CBZ and CBZ-E in vitro was assessed using serum obtained before and at 2, 4 and 8 h after single oral administration of TJ-9 (3 g/kg) by an ultrafiltration method. 4, 6) Preparation of Liver Microsomes Hepatic microsomes were prepared using normal rats or rats pretreated separately with a 2% (w/v) arabic gum solution (vehicle), TJ-9 suspension and PB-saline solution. Briefly, the vehicle (p.o.), (1 g/kg, p.o.) and PB (positive control, 80 mg/kg, i.p.) were administered once a day for 2 weeks (vehicle and TJ-9) or 5 d (PB), and then the liver was excised 24 h after the last pretreatment. Microsomes were prepared by a slight modification of the conventional methodology of Omura and Sato 8) by differential centrifugation. Protein concentrations in microsomes were determined by the method of Lowry et al. 9) with bovine serum albumin as the standard.
Hepatic Enzyme Assays The amounts of CYP and cytochrome b 5 in hepatic microsomes of vehicle-, TJ-9-and PB-pretreated rats were estimated by the method of Omura and Sato. 8) The rate of formation of CBZ-E from CBZ by microsomes was determined with or without various concentrations of TJ-9 (100, 500 or 1000 mg/ml) or erythromycin (2 mM) in the same manner, which we reported previously. 6) Final concentrations of microsomal protein and CBZ were 0.5 mg/ml (final volume of incubation medium: 0.3 ml) and 0.1 mM, respectively, and the incubation time and temperature were 5 min and 37°C, respectively.
Pharmacokinetic Experiments
The left carotid artery of each rat was cannulated with polyethylene tubing (PE-50; Clay Adams, Dickinson & Co., Parsippany, NJ, U.S.A.) under pentobarbital anesthesia (50 mg/kg, intraperitoneally) the day before the pharmacokinetic experiment. The animals were fasted but allowed free access to water for 18 h before the administration of drugs. In the simultaneous administration experiments, a 2% (w/v) arabic gum solution (vehicle) or TJ-9 suspended in the vehicle (1 g/kg) was administered to unanesthetized rats, and then CBZ dissolved in water containing 20% (v/v) ethanol and 50% (v/v) propylene glycol (50 mg/kg) was administered immediately. In repeated pretreatment experiments, the rats were treated with the vehicle or TJ-9 suspension (1 g/kg) once a day for 2 weeks, and then given the CBZ solution 24 h after the last pretreatment. The vehicle, TJ-9 and CBZ were administered orally via gastric intubation. Blood samples (0.25 ml) were collected through the cannula in heparinized plastic microcentrifuge tubes (1.5 ml) before, and 0.25, 0.5, 1, 2, 4, 6, 8, 10, 12 and 24 h after drug administration. The samples were centrifuged at 13000 rpm for 3 min at room temperature in a Centrifuge 5415C (Eppendorf GmbH, Germany), and the plasma fraction was frozen at Ϫ80°C until the assay. The assays were performed within 1 week of collection. Referring to the effective plasma CBZ concentrations at steady state (4-10 mg/ml) during oral administration of a clinical dose in humans, we established the single experimental dose as 50 mg/kg in this study. Also, the dose of TJ-9 (1 g/kg) was determined in accordance with the ratio of the CBZ dose in rats to in humans. The experimental protocol described above was approved by the Experimental Animal Research Committee at Kyoto Pharmaceutical University.
Assay of CBZ and CBZ-E The CBZ and CBZ-E concentrations were determined by HPLC as reported previously. 6) Pharmacokinetic Analysis The peak plasma concentration (C max ) and the time to reach C max (T max ) of CBZ and CBZ-E were obtained from the actual data observed after oral administration. The terminal elimination rate constant (l) was calculated by fitting individual data for three terminal points of the plasma concentration profile with a log-linear regression equation using the least-squares method. The corresponding elimination half-life (t 1/2(l) ) was calculated by dividing ln 2 by l. The areas under the plasma concentrationtime curves from zero to infinity (AUC 0-°) for CBZ and CBZ-E were calculated by means of the trapezoidal rule with extrapolation to infinity with l. The mean residence time from zero to infinity (MRT) for CBZ and CBZ-E was estimated by moment analysis. 10) Measurement of Gastric Emptying Gastric emptying was measured according to the phenol red (PR) method reported by Yokochi et al. 11) with several modifications. Briefly, rats were fasted but allowed free access to water for 24 h before this experiment. A 2% (w/v) arabic gum solution (vehicle; 10 ml/kg) or TJ-9 (0.03 or 1 g/kg) suspended in a constant volume of the vehicle was administered orally to unanesthetized rats, 1 h before the oral administration of the PR solution (100 mg/ml per rat). A BaCl 2 saline solution (positive control; 3.5 mg/kg, i.p.) was injected 5 min before the administration of PR. The rats were killed by cervical dislocation immediately or 15 min after administration of the PR solution, and then a standard stomach (100% PR in the stomach) or test stomach was exposed by laparotomy and quickly ligated at the pylorus and cardia. Each stomach was removed in 10 ml of a 0.1 M Na 2 HPO 4 solution, and the content of the stomach was completely washed out. An aliquot (1 ml) of the solution was added to 2 ml of another 0.1 M Na 2 HPO 4 solution, the mixture vortexed for 5 s (S1), PR solution (1 ml) added to the remainder (9 ml), and the whole solution vortexed for 5 s and diluted 10 times with 0.1 M Na 2 HPO 4 (S2). Then, both S1 and S2 were centrifugated for 10 min (2500ϫg) and the absorbance of their supernatants (OD1 and OD2, respectively) was measured at 570 nm with a spectrophotometer (SPECTRA FLUOR; TECAN). Gastric emptying for each rat was calculated according to the following equations: gastric emptying (%)ϭ[1Ϫ(amount of PR recovered from the test stomach) (average amount of PR recovered from the standard stomachs)
where a and b correspond to the slope and intercept of the calibration curve for PR, respectively. Statistical Analysis Data are expressed as the meanϮstandard error (S.E.). Comparisons between two groups and among more than three groups were performed using the unpaired Student's t-test and one-way or two-way analysis of variance (ANOVA) followed by Scheffe's F-test, respectively, with StatView J5.0 for Macintosh (Abacus Concepts Inc., Berkeley, CA, U.S.A.), and differences were con-sidered statistically significant when pϽ0.05.
RESULTS

Effects of Single Oral Pretreatment with TJ-9 on
Serum Protein Binding of CBZ The in vitro protein binding of CBZ determined using serum obtained from rats pretreated with TJ-9 is shown in Table 1 . No significant differences in the bound fraction of CBZ at two concentrations (1, 10 mg/ml) were observed between the control (0 h) and each time period (2, 4 or 8 h after administration). The protein binding rates of CBZ (about 82%) were similar to those reported previously by us. 4, 6) Effects of TJ-9 on Hepatic Drug-Metabolizing Enzymes The activity of CBZ-10,11-epoxylase against hepatic microsomes obtained from normal rats was significantly reduced by the addition of TJ-9, the inhibitory action being concentration-dependent (Fig. 1) . The TJ-9 concentration for 50% inhibition was estimated as about 540 mg/ml. Also, erythromycin (2 mM), a representative CYP3A inhibitor, significantly inhibited the enzymatic activity (pϽ0.01), the same as TJ-9 at 1000 mg/ml.
Furthermore, we examined the effects of 2-week repeated pretreatment with vehicle, TJ-9 or PB on the wet liver weight, the amounts of CYP and cytochrome b 5 in hepatic microsomes, and the formation of CBZ-E from CBZ by microsomes (Table 2 ). There were no significant differences in the liver/body weight ratio, content of cytochromes or rate of formation of CBZ-E between the control and TJ-9 groups. On the other hand, compared with the control, pretreatment with PB (a representative enzyme inducer) significantly increased the liver weight ratio, CYP content and CBZ-E formed by 23, 252 and 1100%, respectively. The amounts of CYP and cytochrome b 5 in the control group were almost the same as those reported by Ohnishi et al. Figure 2 shows the mean plasma CBZ and CBZ-E concentration-time curves after simultaneous oral administration of CBZ with the vehicle (control) or TJ-9 suspension. The CBZ concentrations in the TJ-9 administration group were lower in the absorption phase (0.25-2 h) than those in the control group (pϽ0.05). In the elimination phase (6-24 h), conversely, the CBZ levels in the TJ-9 administration group tended to be higher. In the case of CBZ-E, the concentrations at 0.25-4 h were lower in the TJ-9 administration than the control group (pϽ0.05). The pharmacokinetic parameters are listed in Table 3 . In the TJ-9 administration group, C max for CBZ and AUC 0-°f or CBZ-E were significantly deccreased by 45 and 32%, respectively (pϽ0.05). T max , l, t 1/2(l) , AUC 0-°a nd MRT for CBZ, and C max , T max , l, t 1/2(l) and MRT for CBZ-E in the TJ-9 administration group were comparable with those in the control Each value represents the meanϮS.E. of 3 rats. Rats were treated orally with a TJ-9 suspension (3 g/kg). Blood was collected before and 2, 4 and 8 h after the treatment. 
12)
Effects of Simultaneous Oral Administration of TJ-9 on CBZ Pharmacokinetics
s F-test).
Rats were pretreated once a day with the vehicle (control, p.o., 2 weeks), TJ-9 suspension (1 g/kg, p.o., 2 weeks) or PB solution (80 mg/kg, i.p., 5 d), and then hepatic microsomes were prepared from each rat 24 h after the last drug treatment.
Fig. 1. Effects of TJ-9 and Erythromycin on the Formation of CBZ-E from CBZ by Hepatic Microsomes in Rats
Each column represents the meanϮS.E. of 5 rats. a) pϽ0.01 vs. control (one-way ANOVA; Scheffe's F-test).
Fig. 2. Effects of Simultaneous Oral Administration of TJ-9 on the Plasma CBZ and CBZ-E Concentrations after Oral Administration of CBZ to Rats
Each point represents the meanϮS.E. of 4 rats. a) pϽ0.05 vs. control (unpaired Student's t-test). The vehicle (control) or TJ-9 suspension (1 g/kg) was administered orally to unanesthetized rats, and then the CBZ solution (50 mg/kg) was administered orally immediately. ᭺, control (CBZ); ᭹, TJ-9 (CBZ); ᭝, control (CBZ-E); ᭡, TJ-9 (CBZ-E). Figure 3 shows plasma CBZ and CBZ-E concentration profiles with 2-week repeated oral pretreatment with the vehicle or TJ-9. The CBZ and CBZ-E concentration-time curves for the two groups were comparable except the initial absorption phase (0.25-1 h) for CBZ. The pharmacokinetic parameters are summarized in Table 4 . There were no significant differences in the value of each parameter for CBZ or CBZ-E between the two groups. Each parameter was also compared between groups given single and repeated treatment with the vehicle, and no significant differences were observed.
group (pϾ0.05).
Effects of Repeated Oral Pretreatment with TJ-9 on CBZ Pharmacokinetics
Effects of TJ-9 on Gastric Emptying The effects of TJ-9 and BaCl 2 on the gastric emptying in rats are shown in Fig.  4 . A single oral administration of TJ-9 reduced the gastric emptying in a dose-dependent manner. The extent in the control (vehicle) group was 89.6Ϯ4.0%. The gastric emptying in the groups treated with 0.03 and 1 g/kg of TJ-9 was 94.6Ϯ2.2 and 55.9Ϯ1.8%, respectively, and the value for the TJ-9 (1 g/kg) group was significantly lower than that for the control group. Furthermore, BaCl 2 (positive control) decreased the gastric emptying, to 65.2Ϯ10.2% (pϽ0.05). 's t-test) . The vehicle (control) or TJ-9 suspension (1 g/kg) was administered orally once a day for 2 weeks to unanesthetized rats, and then the CBZ solution (50 mg/kg) was administered orally 24 h after the last pretreatment. ᭺, control (CBZ); ᭹, TJ-9 (CBZ); ᭝, control (CBZ-E); ᭡, TJ-9 (CBZ-E).
Fig. 4. Effects of TJ-9 and BaCl 2 on Gastric Emptying in Rats
Each column represents the meanϮS.E. of 3-6 rats. a) pϽ0.05, b) pϽ0.005 vs. control (one-way ANOVA; Scheffe's F-test). The vehicle (control) or TJ-9 suspension (0.03 or 1 g/kg) was administered orally to unanesthetized rats, and then the gastric emptying was measured. 's t-test) . The vehicle (control) or TJ-9 suspension (1 g/kg) was administered orally to unanesthetized rats, and then the CBZ solution (50 mg/kg) was immediately administered orally. Each value represents the meanϮS.E. of 9 or 12 rats. The vehicle (control) or TJ-9 suspension (1 g/kg) was administered orally once a day for 2 weeks to unanesthetized rats, and then the CBZ solution (50 mg/kg) was administered orally 24 h after the last pretreatment. DISCUSSION CBZ undergoes an almost complete hepatic and intestinal biotransformation with less than 2% of the dose excreted in both urine and bile remaining unchanged, but the absolute bioavailability after its oral administration is more than 70% in rats, as in humans. 13, 14) Thus, CBZ is believed to have a limited capacity; the total clearance (CL tot ) of CBZ can be regarded as the product of the plasma-unbound fraction (f p ) and intrinsic hepatic clearance (CL int,H ) of CBZ. 15) Hence, a change in CL tot should be accompanied by an increase or decrease in f p and/or CL int,H .
An increase in f P will occur due to displacement in plasma protein binding. The bound fraction of CBZ in serum is relatively high (about 82%; Table 1 ). Valproic acid, indeed, has been reported to displace CBZ from plasma protein binding sites, 16) resulting in the enhancement of the CL tot of CBZ via a significant increase of f p . However, it was confirmed in this study that parent compounds and their various metabolites present in the serum obtained from rats pretreated with a large amount of TJ-9 were unable to displace CBZ from serum protein binding sites ( Table 1 ), indicating that there may be no interaction based on changes in protein binding.
In the case of CBZ, CL int,H is a parameter determined mainly by hepatic metabolism. When administered orally to rats, CBZ is extensively hydrolyzed to CBZ-E prior to excretion in the urine. 13, 17) The addition of TJ-9 to microsomes inhibited CBZ-10,11-epoxylase activity in a concentration-dependent manner in vitro (Fig. 1) . The inhibitory substance(s) against CYP3A activity in TJ-9 has been unidentified. From these observations and results obtained in vitro, it is speculated that some interaction in the process of hepatic and intestinal metabolism might occur in vivo. TJ-9 should generally be administered before meals or between meals, although CBZ is commonly administered after meals in the case of the oral dosage form. Like CBZ, however, TJ-9 must sometimes be taken after meals for certain clinical reasons, e.g., greater compliance. Based on these facts, we examined the effects of simultaneous oral administration of TJ-9 on the plasma CBZ and CBZ-E profiles. TJ-9 co-administration significantly decreased the C max of CBZ and AUC 0-°o f CBZ-E, and lengthened the T max of CBZ, without affecting the elimination rates (Fig. 2, Table 3 ). Furthermore, CBZ has been reported not to be a substrate for multidrug transporter P-glycoprotein (P-gp), 18) and we ruled out the contribution of P-gp to the mechanism of action for pharmacokinetic interaction between TJ-9 and CBZ. Therefore, we investigated the effects of an oral administration of TJ-9 on gastrointestinal motility. As shown in Fig. 4 , TJ-9 (1 g/kg) administered orally reduced the gastric emptying. TJ-9 (0.125-0.5 g/kg) has been reported to have no inhibitory effects on the gastric emptying rate (GER). 19) Nishimura et al. 20) however, reported that TJ-9 (0.25-0.75 g/kg) delayed gastric emptying without regard to the increase of intragastric pH and consequently could decrease gastrointestinal absorption of tolbutamide, speculating that it may be caused by [6] -gingerol, a component of Zingiberis Rhizome which is one of 7 kinds of constituents in TJ-9.
[6]-Gingerol has been reported to inhibit the gastric contraction and reduce the GER via reflection of the action on the central nervous system. 21) Our results were similar to the latter findings. 20) Accordingly, it was considered that a reduced and slowed absorption of CBZ might be attributed to the decrease in gastric emptying induced by TJ-9. With CBZ-E, the concentration at all time points and the AUC 0-°w ere lower in the TJ-9 administration group than the control group. This may be due to the delay and decrease of CBZ absorption. On the other hand, the results in vitro with liver microsomes are inconsistent with those in vivo. The reason why the results are different might be that the final concentration of some unknown inhibitory substance(s) at the site of action in vivo is much lower than that under experimental conditions in vitro, or that the inhibitor(s), which TJ-9 itself may contain, extensively decreases in concentration through presystemic first-pass metabolism when TJ-9 is administered orally. Further investigation should be undertaken to examine this contradiction. On the other hand, 2-week repeated pretreatment with TJ-9 influenced neither the contents of cytochromes and formation of CBZ-E in hepatic microsomes (Table 2) , the plasma concentration-time profile (Fig. 3) , nor any of the pharmacokinetic parameters of CBZ or CBZ-E (Table 4) , and the findings in vitro corresponded to those in vivo, suggesting little possibility of hepatic CYP3A induction by chronic pretreatment with TJ-9. In these 2-week pretreatment experiments, as well as in the simultaneous administration experiments, the CBZ concentration in the initial absorption phase was significantly decreased by the administration of TJ-9 (Fig. 3) . This may be due to the pretreatment for 2 weeks with a much larger amount of TJ-9 than its clinical dose or the induction of intestinal CYP3A by TJ-9.
The overall rate of biotransformation of CBZ in rats is markedly different from that in humans; the metabolic clearance is more than 10-fold faster in rats.
13) The major pathways, however, are qualitatively similar in both species. 17) The hepatic isoenzyme most responsible for the formation of CBZ-E in humans has been identified as CYP3A4. 3) In rats, as well as in humans, CYP3A isoforms are known to metabolize CBZ. 22, 23) Therefore, the result that TJ-9 had no effect on the metabolism of CBZ in rats is considered to be applicable to humans.
In conclusion, it was confirmed that simultaneous oral administration of TJ-9 with CBZ to rats decreased gastrointestinal absorption of CBZ, at least in part, by reducing the GER, without affecting the metabolism of CBZ.
